Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1222 Single Dose Study in Healthy Subjects
NCT03870100Phase 1Completed
- Sponsor
- Hengrui
- Start
- Apr 2019
- Primary completion
- Oct 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR-1222 in osteoporosis (5 cohorts), sponsored by Hengrui. Primary endpoint: Number & proportion of subjects with adverse events. Started Apr 2019; status: completed.
02
Drugs
SHR-1222
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT03870100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03870100.